PVLA
NASDAQPalvella Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings12
News · 26 weeks69+125%
2026-03-012026-08-23
Mix3190d
- Insider12(39%)
- Other9(29%)
- SEC Filings6(19%)
- Earnings2(6%)
- Leadership1(3%)
- Offering1(3%)
Latest news
25 items- INSIDERChief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $654,791 worth of shares (4,302 units at $152.21) as part of a pre-agreed trading plan (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palvella Therapeutics Inc.SCHEDULE 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)
- SECSEC Form SCHEDULE 13G filed by Palvella Therapeutics Inc.SCHEDULE 13G - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)
- PRPalvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceWAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's websit
- SECSEC Form S-8 filed by Palvella Therapeutics Inc.S-8 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- SECSEC Form 10-Q filed by Palvella Therapeutics Inc.10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- PRPalvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateFirst module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026 Topline results from the Phase 2 LOTU t
- SECSEC Form SCHEDULE 13G filed by Palvella Therapeutics Inc.SCHEDULE 13G - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)
- PRPalvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug RepurposingHybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for significant unmet medical needs Dr. Martini to discuss evidence frameworks and regulatory approaches for advancing repurposed therapies for patients with serious, rare diseases Meeting builds on FDA’s May 2026 drug repurposing initiative focused on advancing new uses for approved medicines, particularly in chronic or rare diseases with significant unmet medical needs WAYNE, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA
- PRPalvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast, including presentation slides, ple
- INSIDERChief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $642,191 worth of shares (4,302 units at $149.28) as part of a pre-agreed trading plan (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- INSIDERSEC Form 4 filed by Director Pauls Matthew4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pauls Matthew3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- PRPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease experience, including executive and Board roles at Savara Inc. (NASDAQ:SVRA), Soleno Therapeutics (NASDAQ:SLNO), Strongbridge Biopharma (NASDAQ:SBBP) and Insmed Incorporated (NASDAQ:INSM) WAYNE, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which th
- PRPalvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsFDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy and Fast Track designations for QTORIN™ rapamycin, providing an expedited development and review pathway based on its potential to address a serious unmet medical need Palvella remains on track to complete the NDA submission in the second half of 2026 while accelerating U.S. launch readiness for a potential standalone commercial launch of QTORIN™ rapamycin in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy an
- INSIDERChief Operating Officer Goin Kathleen sold $476,373 worth of shares (4,302 units at $110.73) as part of a pre-agreed trading plan and exercised 4,302 shares at a strike of $8.11 (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- PRFDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic MalformationsFDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on track to complete the NDA submission in the second half of 2026 QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare
- INSIDERCFO, Treasurer Korenberg Matthew E exercised 1,000 shares at a strike of $13.60 (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- INSIDERSEC Form 4 filed by Director Kiritsy Christopher P4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Jenkins George M4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Heron Elaine J4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
PVLA FAQ
5 questionsWhere does PVLA stock trade?
Palvella Therapeutics Inc. (PVLA) is listed on NASDAQ.What sector and industry is PVLA in?
Palvella Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PVLA?
Palvella Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stephens: Overweight on 2026-05-12.What companies are similar to PVLA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PVLA side-by-side with any of them on Quantisnow.How can I track PVLA on Quantisnow?
Quantisnow aggregates Palvella Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PVLA to receive live email and push alerts on every new disclosure.